| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 187 | 2025 | 974 | 34.230 |
Why?
|
| Homosexuality, Male | 124 | 2023 | 332 | 25.140 |
Why?
|
| Pre-Exposure Prophylaxis | 55 | 2024 | 186 | 17.120 |
Why?
|
| Sexual and Gender Minorities | 63 | 2025 | 250 | 14.010 |
Why?
|
| Social Networking | 42 | 2025 | 85 | 10.380 |
Why?
|
| Anti-HIV Agents | 31 | 2025 | 199 | 10.080 |
Why?
|
| Sexual Behavior | 60 | 2025 | 334 | 8.740 |
Why?
|
| Transgender Persons | 23 | 2025 | 132 | 7.640 |
Why?
|
| Social Support | 28 | 2025 | 239 | 5.990 |
Why?
|
| Chicago | 72 | 2025 | 1503 | 5.760 |
Why?
|
| Young Adult | 119 | 2025 | 7025 | 4.770 |
Why?
|
| Risk-Taking | 35 | 2021 | 163 | 4.360 |
Why?
|
| Syphilis | 10 | 2023 | 36 | 4.210 |
Why?
|
| Contact Tracing | 12 | 2023 | 29 | 4.160 |
Why?
|
| Male | 212 | 2025 | 45870 | 3.940 |
Why?
|
| Disease Transmission, Infectious | 11 | 2019 | 60 | 3.740 |
Why?
|
| Adolescent | 97 | 2025 | 9896 | 3.730 |
Why?
|
| Sexual Partners | 25 | 2024 | 106 | 3.720 |
Why?
|
| Substance-Related Disorders | 15 | 2025 | 451 | 3.670 |
Why?
|
| Adult | 165 | 2025 | 28718 | 3.540 |
Why?
|
| Patient Acceptance of Health Care | 18 | 2025 | 296 | 3.490 |
Why?
|
| Unsafe Sex | 17 | 2023 | 45 | 3.210 |
Why?
|
| Sexually Transmitted Diseases | 14 | 2023 | 111 | 3.150 |
Why?
|
| Humans | 269 | 2025 | 96127 | 3.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 26 | 2022 | 569 | 3.000 |
Why?
|
| Opioid-Related Disorders | 14 | 2025 | 232 | 2.910 |
Why?
|
| Continuity of Patient Care | 9 | 2021 | 180 | 2.750 |
Why?
|
| Residence Characteristics | 12 | 2024 | 213 | 2.710 |
Why?
|
| Social Stigma | 15 | 2025 | 86 | 2.700 |
Why?
|
| Viral Load | 11 | 2024 | 164 | 2.500 |
Why?
|
| Medication Adherence | 8 | 2022 | 122 | 2.410 |
Why?
|
| Peer Group | 7 | 2025 | 94 | 2.250 |
Why?
|
| HIV-1 | 9 | 2025 | 182 | 2.210 |
Why?
|
| Social Media | 8 | 2025 | 111 | 2.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 7 | 2023 | 80 | 2.050 |
Why?
|
| Safe Sex | 7 | 2020 | 24 | 2.030 |
Why?
|
| Criminals | 4 | 2024 | 34 | 2.020 |
Why?
|
| Health Promotion | 10 | 2020 | 176 | 1.980 |
Why?
|
| Female | 107 | 2025 | 50063 | 1.910 |
Why?
|
| United States | 48 | 2025 | 7767 | 1.770 |
Why?
|
| Papillomavirus Infections | 8 | 2022 | 301 | 1.730 |
Why?
|
| HIV Seropositivity | 8 | 2020 | 53 | 1.730 |
Why?
|
| Cross-Sectional Studies | 27 | 2025 | 1874 | 1.580 |
Why?
|
| Cohort Studies | 23 | 2025 | 3107 | 1.510 |
Why?
|
| Middle Aged | 70 | 2025 | 28363 | 1.500 |
Why?
|
| Internet | 7 | 2021 | 339 | 1.470 |
Why?
|
| Circumcision, Male | 5 | 2013 | 20 | 1.440 |
Why?
|
| Public Opinion | 4 | 2025 | 51 | 1.430 |
Why?
|
| Marijuana Use | 2 | 2025 | 12 | 1.410 |
Why?
|
| Socioeconomic Factors | 16 | 2023 | 639 | 1.360 |
Why?
|
| India | 17 | 2018 | 138 | 1.340 |
Why?
|
| Health Status Disparities | 6 | 2020 | 221 | 1.330 |
Why?
|
| Drug Overdose | 6 | 2025 | 89 | 1.310 |
Why?
|
| Automobile Driving | 5 | 2014 | 33 | 1.300 |
Why?
|
| Criminal Law | 5 | 2023 | 14 | 1.280 |
Why?
|
| Surveys and Questionnaires | 27 | 2025 | 2860 | 1.270 |
Why?
|
| Logistic Models | 17 | 2020 | 1268 | 1.260 |
Why?
|
| Referral and Consultation | 6 | 2021 | 386 | 1.250 |
Why?
|
| Condoms | 7 | 2019 | 39 | 1.170 |
Why?
|
| Longitudinal Studies | 17 | 2025 | 1175 | 1.160 |
Why?
|
| Risk Factors | 25 | 2023 | 5960 | 1.150 |
Why?
|
| Crime | 4 | 2024 | 38 | 1.140 |
Why?
|
| Anus Neoplasms | 3 | 2019 | 38 | 1.080 |
Why?
|
| Health Services Accessibility | 9 | 2025 | 491 | 1.050 |
Why?
|
| Coinfection | 4 | 2023 | 67 | 1.040 |
Why?
|
| Marijuana Abuse | 2 | 2025 | 30 | 1.030 |
Why?
|
| Prevalence | 19 | 2024 | 1349 | 1.030 |
Why?
|
| Cell Phone | 4 | 2018 | 38 | 1.020 |
Why?
|
| HIV Seronegativity | 3 | 2020 | 14 | 1.010 |
Why?
|
| Substance Abuse, Intravenous | 7 | 2021 | 66 | 1.010 |
Why?
|
| Stress, Psychological | 6 | 2021 | 345 | 0.960 |
Why?
|
| Epidemics | 4 | 2023 | 41 | 0.950 |
Why?
|
| Motor Vehicles | 4 | 2012 | 19 | 0.920 |
Why?
|
| Family Relations | 2 | 2016 | 38 | 0.890 |
Why?
|
| Cooperative Behavior | 3 | 2023 | 197 | 0.880 |
Why?
|
| Incidence | 13 | 2022 | 1715 | 0.880 |
Why?
|
| Violence | 2 | 2018 | 154 | 0.850 |
Why?
|
| HIV | 8 | 2022 | 49 | 0.850 |
Why?
|
| Cannabis | 2 | 2023 | 40 | 0.840 |
Why?
|
| Health Equity | 2 | 2024 | 103 | 0.830 |
Why?
|
| Exposure to Violence | 3 | 2024 | 14 | 0.830 |
Why?
|
| Health Surveys | 8 | 2019 | 245 | 0.810 |
Why?
|
| Communication | 4 | 2025 | 477 | 0.800 |
Why?
|
| Authorship | 1 | 2023 | 26 | 0.800 |
Why?
|
| Herpes Genitalis | 3 | 2015 | 41 | 0.790 |
Why?
|
| Hand Disinfection | 2 | 2021 | 18 | 0.790 |
Why?
|
| Drug Users | 5 | 2025 | 30 | 0.780 |
Why?
|
| Papillomaviridae | 4 | 2022 | 180 | 0.770 |
Why?
|
| Risk Assessment | 8 | 2021 | 2480 | 0.770 |
Why?
|
| Rural Population | 8 | 2025 | 171 | 0.740 |
Why?
|
| Skin Pigmentation | 2 | 2019 | 36 | 0.740 |
Why?
|
| Social Capital | 2 | 2021 | 3 | 0.730 |
Why?
|
| Social Work | 2 | 2019 | 22 | 0.730 |
Why?
|
| Gambling | 1 | 2025 | 168 | 0.720 |
Why?
|
| Viremia | 1 | 2021 | 53 | 0.710 |
Why?
|
| Urban Population | 5 | 2018 | 240 | 0.710 |
Why?
|
| Sexuality | 1 | 2021 | 42 | 0.700 |
Why?
|
| Masks | 1 | 2021 | 31 | 0.700 |
Why?
|
| Ambulatory Care Facilities | 3 | 2020 | 118 | 0.700 |
Why?
|
| Pandemics | 14 | 2024 | 880 | 0.700 |
Why?
|
| Interpersonal Relations | 4 | 2020 | 182 | 0.700 |
Why?
|
| Travel | 2 | 2018 | 72 | 0.690 |
Why?
|
| Motivation | 4 | 2019 | 310 | 0.690 |
Why?
|
| Anus Diseases | 2 | 2022 | 16 | 0.690 |
Why?
|
| Sleep Wake Disorders | 1 | 2022 | 128 | 0.670 |
Why?
|
| Trust | 5 | 2025 | 101 | 0.670 |
Why?
|
| Racism | 3 | 2019 | 105 | 0.670 |
Why?
|
| Gender Identity | 5 | 2025 | 60 | 0.670 |
Why?
|
| Emergency Service, Hospital | 4 | 2023 | 594 | 0.660 |
Why?
|
| Health Status | 4 | 2021 | 386 | 0.660 |
Why?
|
| Bisexuality | 6 | 2020 | 36 | 0.650 |
Why?
|
| Drug Prescriptions | 2 | 2020 | 151 | 0.640 |
Why?
|
| Resilience, Psychological | 1 | 2020 | 35 | 0.640 |
Why?
|
| Health Behavior | 5 | 2023 | 191 | 0.630 |
Why?
|
| Primary Prevention | 1 | 2020 | 86 | 0.630 |
Why?
|
| Electronic Health Records | 5 | 2023 | 372 | 0.630 |
Why?
|
| Communicable Disease Control | 3 | 2022 | 56 | 0.620 |
Why?
|
| Delivery of Health Care | 3 | 2019 | 469 | 0.580 |
Why?
|
| Analgesics, Opioid | 8 | 2025 | 513 | 0.580 |
Why?
|
| Sex Workers | 2 | 2021 | 9 | 0.580 |
Why?
|
| Texas | 7 | 2022 | 131 | 0.570 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2017 | 64 | 0.570 |
Why?
|
| Heterosexuality | 1 | 2018 | 21 | 0.570 |
Why?
|
| Patient Compliance | 4 | 2021 | 239 | 0.570 |
Why?
|
| Healthcare Disparities | 5 | 2019 | 490 | 0.570 |
Why?
|
| Aged | 19 | 2025 | 20964 | 0.560 |
Why?
|
| Models, Psychological | 2 | 2016 | 166 | 0.550 |
Why?
|
| Epidemiologic Methods | 1 | 2018 | 60 | 0.550 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 25 | 0.540 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 422 | 0.540 |
Why?
|
| Illinois | 8 | 2024 | 531 | 0.530 |
Why?
|
| Mass Screening | 7 | 2021 | 710 | 0.530 |
Why?
|
| Reproductive Health | 1 | 2018 | 37 | 0.530 |
Why?
|
| Greece | 8 | 2022 | 20 | 0.530 |
Why?
|
| Text Messaging | 2 | 2015 | 35 | 0.520 |
Why?
|
| Anti-Retroviral Agents | 4 | 2018 | 35 | 0.520 |
Why?
|
| Louisiana | 4 | 2020 | 18 | 0.510 |
Why?
|
| Uncertainty | 1 | 2017 | 82 | 0.510 |
Why?
|
| Penile Neoplasms | 1 | 2016 | 19 | 0.500 |
Why?
|
| Health Care Reform | 1 | 2017 | 86 | 0.490 |
Why?
|
| Tenofovir | 3 | 2022 | 16 | 0.480 |
Why?
|
| Urban Health | 2 | 2013 | 55 | 0.480 |
Why?
|
| Pharmaceutical Preparations | 3 | 2022 | 97 | 0.480 |
Why?
|
| Mother-Child Relations | 1 | 2015 | 31 | 0.470 |
Why?
|
| Pilot Projects | 4 | 2024 | 938 | 0.460 |
Why?
|
| Central Nervous System Stimulants | 3 | 2023 | 235 | 0.460 |
Why?
|
| Psychoanalytic Theory | 1 | 2015 | 2 | 0.460 |
Why?
|
| Psychoanalytic Therapy | 1 | 2015 | 3 | 0.460 |
Why?
|
| Chemoprevention | 1 | 2015 | 93 | 0.460 |
Why?
|
| Group Processes | 1 | 2015 | 31 | 0.450 |
Why?
|
| Geographic Information Systems | 4 | 2024 | 28 | 0.450 |
Why?
|
| Social Identification | 1 | 2015 | 29 | 0.450 |
Why?
|
| Bias | 2 | 2020 | 139 | 0.440 |
Why?
|
| Thinking | 1 | 2015 | 39 | 0.440 |
Why?
|
| Interviews as Topic | 7 | 2023 | 376 | 0.440 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2016 | 149 | 0.430 |
Why?
|
| Self Disclosure | 1 | 2014 | 32 | 0.430 |
Why?
|
| Sociometric Techniques | 1 | 2014 | 3 | 0.430 |
Why?
|
| Women's Health | 1 | 2015 | 109 | 0.430 |
Why?
|
| Multiple Trauma | 1 | 2014 | 38 | 0.430 |
Why?
|
| Spinal Injuries | 1 | 2014 | 29 | 0.430 |
Why?
|
| Electronic Mail | 1 | 2014 | 17 | 0.420 |
Why?
|
| Patient Participation | 1 | 2016 | 241 | 0.420 |
Why?
|
| Transportation | 3 | 2013 | 20 | 0.420 |
Why?
|
| Complementary Therapies | 1 | 2014 | 55 | 0.420 |
Why?
|
| Quality Improvement | 2 | 2017 | 502 | 0.410 |
Why?
|
| Restaurants | 1 | 2013 | 6 | 0.410 |
Why?
|
| Alcohol Drinking | 3 | 2024 | 287 | 0.400 |
Why?
|
| Attitude | 4 | 2023 | 137 | 0.400 |
Why?
|
| Multivariate Analysis | 5 | 2021 | 1010 | 0.400 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 319 | 0.400 |
Why?
|
| Decision Making | 2 | 2016 | 694 | 0.390 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2014 | 118 | 0.390 |
Why?
|
| Depression | 2 | 2022 | 560 | 0.390 |
Why?
|
| Mexican Americans | 1 | 2013 | 70 | 0.390 |
Why?
|
| Comorbidity | 5 | 2023 | 1011 | 0.390 |
Why?
|
| Seroepidemiologic Studies | 4 | 2019 | 57 | 0.370 |
Why?
|
| Friends | 1 | 2012 | 21 | 0.370 |
Why?
|
| Marriage | 1 | 2012 | 25 | 0.370 |
Why?
|
| Retrospective Studies | 9 | 2025 | 10286 | 0.370 |
Why?
|
| Program Evaluation | 3 | 2023 | 323 | 0.360 |
Why?
|
| Cervical Vertebrae | 1 | 2014 | 232 | 0.360 |
Why?
|
| Perception | 4 | 2020 | 185 | 0.350 |
Why?
|
| Video Recording | 1 | 2012 | 214 | 0.340 |
Why?
|
| Quality of Health Care | 4 | 2017 | 404 | 0.340 |
Why?
|
| Counseling | 1 | 2012 | 174 | 0.330 |
Why?
|
| Population Dynamics | 1 | 2011 | 144 | 0.330 |
Why?
|
| Prisoners | 2 | 2023 | 48 | 0.330 |
Why?
|
| Risk Reduction Behavior | 4 | 2018 | 99 | 0.330 |
Why?
|
| Health Services Research | 2 | 2008 | 148 | 0.310 |
Why?
|
| Self Efficacy | 2 | 2022 | 61 | 0.310 |
Why?
|
| Cities | 5 | 2022 | 57 | 0.300 |
Why?
|
| Poverty | 2 | 2021 | 196 | 0.300 |
Why?
|
| Hygiene | 1 | 2009 | 10 | 0.300 |
Why?
|
| Papillomavirus Vaccines | 2 | 2021 | 59 | 0.300 |
Why?
|
| Age Factors | 3 | 2018 | 1963 | 0.290 |
Why?
|
| Atherosclerosis | 3 | 2021 | 271 | 0.290 |
Why?
|
| Nitrites | 2 | 2018 | 34 | 0.290 |
Why?
|
| AIDS Serodiagnosis | 2 | 2020 | 27 | 0.280 |
Why?
|
| Sleep | 2 | 2022 | 458 | 0.280 |
Why?
|
| Minority Groups | 2 | 2022 | 154 | 0.280 |
Why?
|
| Male Urogenital Diseases | 1 | 2007 | 8 | 0.280 |
Why?
|
| Cluster Analysis | 4 | 2023 | 392 | 0.280 |
Why?
|
| Gingiva | 1 | 2007 | 8 | 0.280 |
Why?
|
| Alcoholism | 2 | 2020 | 191 | 0.270 |
Why?
|
| Female Urogenital Diseases | 1 | 2007 | 9 | 0.270 |
Why?
|
| AIDS Vaccines | 1 | 2007 | 15 | 0.270 |
Why?
|
| Rural Health | 1 | 2007 | 19 | 0.270 |
Why?
|
| Insurance, Health | 2 | 2020 | 182 | 0.270 |
Why?
|
| Sex Work | 3 | 2018 | 12 | 0.270 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2008 | 74 | 0.270 |
Why?
|
| HIV Antibodies | 1 | 2007 | 39 | 0.270 |
Why?
|
| Cervix Uteri | 1 | 2007 | 73 | 0.270 |
Why?
|
| Naloxone | 2 | 2024 | 72 | 0.260 |
Why?
|
| Attitude to Health | 2 | 2023 | 226 | 0.260 |
Why?
|
| Schools | 2 | 2021 | 84 | 0.260 |
Why?
|
| France | 7 | 2019 | 54 | 0.260 |
Why?
|
| Gift Giving | 1 | 2006 | 5 | 0.250 |
Why?
|
| Odds Ratio | 5 | 2018 | 713 | 0.250 |
Why?
|
| Community-Based Participatory Research | 2 | 2020 | 38 | 0.240 |
Why?
|
| Rilpivirine | 1 | 2025 | 6 | 0.240 |
Why?
|
| Drug Industry | 1 | 2006 | 59 | 0.240 |
Why?
|
| Sex Factors | 3 | 2020 | 1133 | 0.240 |
Why?
|
| Age Distribution | 2 | 2023 | 209 | 0.230 |
Why?
|
| Social Perception | 1 | 2006 | 94 | 0.230 |
Why?
|
| Geography | 2 | 2021 | 240 | 0.230 |
Why?
|
| Fuzzy Logic | 1 | 2025 | 16 | 0.230 |
Why?
|
| Medical Marijuana | 1 | 2025 | 9 | 0.230 |
Why?
|
| Patient-Centered Care | 2 | 2019 | 228 | 0.230 |
Why?
|
| Research Personnel | 2 | 2023 | 84 | 0.230 |
Why?
|
| Pyridones | 1 | 2025 | 68 | 0.230 |
Why?
|
| Self Report | 2 | 2025 | 328 | 0.230 |
Why?
|
| HIV Seroprevalence | 2 | 2018 | 9 | 0.220 |
Why?
|
| Models, Theoretical | 5 | 2021 | 503 | 0.220 |
Why?
|
| Phylogeny | 6 | 2020 | 1275 | 0.220 |
Why?
|
| Qualitative Research | 4 | 2024 | 361 | 0.220 |
Why?
|
| Public Health | 4 | 2023 | 155 | 0.210 |
Why?
|
| Quality of Life | 3 | 2024 | 1816 | 0.210 |
Why?
|
| Hospitals, Rural | 1 | 2004 | 8 | 0.210 |
Why?
|
| Ethics, Medical | 1 | 2006 | 312 | 0.200 |
Why?
|
| Time Factors | 4 | 2019 | 5585 | 0.200 |
Why?
|
| Occupational Health | 2 | 2014 | 40 | 0.200 |
Why?
|
| Physicians | 2 | 2025 | 707 | 0.200 |
Why?
|
| Health Risk Behaviors | 2 | 2020 | 6 | 0.200 |
Why?
|
| Anal Canal | 3 | 2022 | 92 | 0.200 |
Why?
|
| Narcotic Antagonists | 1 | 2024 | 170 | 0.200 |
Why?
|
| Otolaryngology | 3 | 2016 | 56 | 0.200 |
Why?
|
| Vaccination | 3 | 2022 | 311 | 0.190 |
Why?
|
| Sexual Health | 1 | 2023 | 20 | 0.190 |
Why?
|
| Patient Transfer | 1 | 2004 | 108 | 0.190 |
Why?
|
| Herpesvirus 2, Human | 2 | 2015 | 45 | 0.190 |
Why?
|
| Internal Medicine | 1 | 2006 | 371 | 0.190 |
Why?
|
| Smartphone | 3 | 2019 | 54 | 0.190 |
Why?
|
| Quality Indicators, Health Care | 1 | 2004 | 155 | 0.190 |
Why?
|
| Population Surveillance | 2 | 2022 | 218 | 0.190 |
Why?
|
| Mental Health | 1 | 2024 | 202 | 0.190 |
Why?
|
| Urinary Bladder Diseases | 1 | 2022 | 42 | 0.190 |
Why?
|
| Vulnerable Populations | 2 | 2020 | 94 | 0.180 |
Why?
|
| Infectious Disease Medicine | 1 | 2021 | 8 | 0.180 |
Why?
|
| Data Collection | 2 | 2014 | 381 | 0.180 |
Why?
|
| Homicide | 1 | 2022 | 54 | 0.180 |
Why?
|
| Capacity Building | 1 | 2021 | 12 | 0.180 |
Why?
|
| Rhinitis | 2 | 2017 | 186 | 0.170 |
Why?
|
| Human papillomavirus 18 | 2 | 2022 | 22 | 0.170 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 45 | 0.170 |
Why?
|
| Focus Groups | 3 | 2023 | 189 | 0.170 |
Why?
|
| San Francisco | 1 | 2020 | 26 | 0.170 |
Why?
|
| Sinusitis | 2 | 2017 | 223 | 0.170 |
Why?
|
| Emtricitabine | 1 | 2020 | 10 | 0.170 |
Why?
|
| Human papillomavirus 16 | 2 | 2022 | 45 | 0.170 |
Why?
|
| Software | 2 | 2023 | 698 | 0.170 |
Why?
|
| Prospective Studies | 4 | 2023 | 4671 | 0.170 |
Why?
|
| Health Education | 2 | 2019 | 107 | 0.170 |
Why?
|
| DNA, Viral | 2 | 2018 | 274 | 0.170 |
Why?
|
| Probability | 1 | 2021 | 365 | 0.170 |
Why?
|
| Sex Characteristics | 1 | 2023 | 339 | 0.170 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 173 | 0.170 |
Why?
|
| Methamphetamine | 1 | 2022 | 104 | 0.160 |
Why?
|
| Mentoring | 1 | 2021 | 35 | 0.160 |
Why?
|
| Rural Health Services | 1 | 2020 | 17 | 0.160 |
Why?
|
| Natural Language Processing | 1 | 2021 | 42 | 0.160 |
Why?
|
| Suicide | 1 | 2022 | 162 | 0.160 |
Why?
|
| Psychological Theory | 1 | 2020 | 23 | 0.160 |
Why?
|
| Psychotherapy, Brief | 1 | 2020 | 13 | 0.160 |
Why?
|
| Universities | 2 | 2019 | 154 | 0.160 |
Why?
|
| Intensive Care Units | 1 | 2004 | 460 | 0.160 |
Why?
|
| Practice Patterns, Physicians' | 4 | 2025 | 647 | 0.160 |
Why?
|
| Social Norms | 1 | 2019 | 15 | 0.160 |
Why?
|
| Marijuana Smoking | 2 | 2018 | 28 | 0.160 |
Why?
|
| Hospitals, Urban | 1 | 2020 | 64 | 0.160 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 3927 | 0.160 |
Why?
|
| Forecasting | 1 | 2020 | 317 | 0.150 |
Why?
|
| Public Health Practice | 1 | 2019 | 11 | 0.150 |
Why?
|
| Eligibility Determination | 1 | 2019 | 38 | 0.150 |
Why?
|
| Coronary Vessels | 1 | 2021 | 201 | 0.150 |
Why?
|
| Treatment Outcome | 5 | 2020 | 9173 | 0.150 |
Why?
|
| Patient Navigation | 1 | 2019 | 16 | 0.150 |
Why?
|
| Professional-Patient Relations | 1 | 2019 | 54 | 0.150 |
Why?
|
| Genetic Testing | 1 | 2023 | 565 | 0.150 |
Why?
|
| Housing | 1 | 2019 | 50 | 0.150 |
Why?
|
| Health Expenditures | 1 | 2020 | 101 | 0.150 |
Why?
|
| Awareness | 1 | 2019 | 90 | 0.150 |
Why?
|
| Community Health Centers | 1 | 2020 | 120 | 0.150 |
Why?
|
| Geographic Mapping | 1 | 2018 | 14 | 0.140 |
Why?
|
| Equipment Design | 2 | 2018 | 427 | 0.140 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2018 | 25 | 0.140 |
Why?
|
| Truth Disclosure | 1 | 2019 | 92 | 0.140 |
Why?
|
| Sex Distribution | 1 | 2018 | 175 | 0.140 |
Why?
|
| Organizational Affiliation | 1 | 2018 | 6 | 0.140 |
Why?
|
| Demography | 1 | 2018 | 189 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 2 | 2018 | 908 | 0.140 |
Why?
|
| China | 2 | 2009 | 264 | 0.140 |
Why?
|
| Models, Statistical | 3 | 2019 | 594 | 0.140 |
Why?
|
| Unemployment | 1 | 2017 | 11 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 501 | 0.140 |
Why?
|
| Personhood | 1 | 2017 | 17 | 0.130 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2017 | 9 | 0.130 |
Why?
|
| New York City | 3 | 2025 | 69 | 0.130 |
Why?
|
| Police | 1 | 2017 | 25 | 0.130 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 47 | 0.130 |
Why?
|
| Health Services Administration | 1 | 2017 | 2 | 0.130 |
Why?
|
| Financing, Organized | 1 | 2017 | 13 | 0.130 |
Why?
|
| Hepatitis C | 1 | 2019 | 185 | 0.130 |
Why?
|
| Genotype | 2 | 2018 | 1882 | 0.130 |
Why?
|
| Personal Satisfaction | 1 | 2017 | 66 | 0.130 |
Why?
|
| Community Health Services | 1 | 2018 | 81 | 0.130 |
Why?
|
| Internship and Residency | 1 | 2006 | 1134 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2016 | 74 | 0.120 |
Why?
|
| Physician-Patient Relations | 2 | 2016 | 635 | 0.120 |
Why?
|
| Calcium | 1 | 2021 | 1205 | 0.120 |
Why?
|
| Likelihood Functions | 1 | 2016 | 257 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2017 | 120 | 0.120 |
Why?
|
| Cues | 1 | 2017 | 189 | 0.120 |
Why?
|
| Transsexualism | 1 | 2016 | 37 | 0.120 |
Why?
|
| Cocaine-Related Disorders | 1 | 2016 | 41 | 0.120 |
Why?
|
| Reimbursement, Incentive | 1 | 2016 | 39 | 0.120 |
Why?
|
| Instinct | 1 | 2015 | 2 | 0.120 |
Why?
|
| Body Mass Index | 1 | 2019 | 815 | 0.120 |
Why?
|
| Medicaid | 1 | 2018 | 260 | 0.120 |
Why?
|
| Crime Victims | 1 | 2016 | 56 | 0.110 |
Why?
|
| Treponema pallidum | 1 | 2015 | 8 | 0.110 |
Why?
|
| Psychotherapy, Group | 1 | 2015 | 37 | 0.110 |
Why?
|
| Bayes Theorem | 1 | 2016 | 404 | 0.110 |
Why?
|
| Paris | 3 | 2019 | 5 | 0.110 |
Why?
|
| Medicare | 1 | 2018 | 458 | 0.110 |
Why?
|
| Ukraine | 3 | 2019 | 22 | 0.110 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 155 | 0.110 |
Why?
|
| Needs Assessment | 1 | 2016 | 171 | 0.110 |
Why?
|
| Trauma, Nervous System | 1 | 2014 | 11 | 0.110 |
Why?
|
| Atlanto-Occipital Joint | 1 | 2014 | 4 | 0.110 |
Why?
|
| Atlanto-Axial Joint | 1 | 2014 | 14 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 484 | 0.110 |
Why?
|
| Trauma Severity Indices | 1 | 2014 | 47 | 0.110 |
Why?
|
| Ligaments, Articular | 1 | 2014 | 42 | 0.110 |
Why?
|
| Health Services | 2 | 2019 | 58 | 0.110 |
Why?
|
| Causality | 1 | 2014 | 84 | 0.110 |
Why?
|
| Neoplasms | 2 | 2021 | 3250 | 0.110 |
Why?
|
| Cognition | 1 | 2019 | 635 | 0.100 |
Why?
|
| Community Participation | 1 | 2014 | 41 | 0.100 |
Why?
|
| Craniocerebral Trauma | 1 | 2014 | 60 | 0.100 |
Why?
|
| Albuterol | 1 | 2014 | 35 | 0.100 |
Why?
|
| Interdisciplinary Communication | 1 | 2014 | 135 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 2473 | 0.100 |
Why?
|
| Bronchodilator Agents | 1 | 2014 | 70 | 0.100 |
Why?
|
| Thoracic Vertebrae | 1 | 2014 | 91 | 0.100 |
Why?
|
| Lactic Acid | 1 | 2014 | 108 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 2040 | 0.100 |
Why?
|
| Drama | 1 | 2013 | 7 | 0.100 |
Why?
|
| Harm Reduction | 2 | 2024 | 29 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 935 | 0.100 |
Why?
|
| Delphi Technique | 1 | 2013 | 136 | 0.100 |
Why?
|
| Fentanyl | 2 | 2025 | 87 | 0.100 |
Why?
|
| Case Management | 2 | 2024 | 29 | 0.100 |
Why?
|
| Trauma Centers | 1 | 2014 | 174 | 0.100 |
Why?
|
| Joint Instability | 1 | 2014 | 99 | 0.100 |
Why?
|
| Machine Learning | 3 | 2021 | 347 | 0.100 |
Why?
|
| Occupations | 1 | 2012 | 25 | 0.090 |
Why?
|
| Telephone | 1 | 2012 | 36 | 0.090 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2012 | 10 | 0.090 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2012 | 26 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2016 | 3041 | 0.090 |
Why?
|
| Prejudice | 1 | 2012 | 49 | 0.090 |
Why?
|
| Spouses | 1 | 2012 | 32 | 0.090 |
Why?
|
| Leadership | 1 | 2014 | 159 | 0.090 |
Why?
|
| Tracheostomy | 1 | 2012 | 46 | 0.090 |
Why?
|
| Child | 2 | 2020 | 7626 | 0.090 |
Why?
|
| Extramarital Relations | 1 | 2011 | 1 | 0.090 |
Why?
|
| Treatment Failure | 1 | 2012 | 297 | 0.090 |
Why?
|
| Coitus | 1 | 2011 | 20 | 0.090 |
Why?
|
| Epidemiologic Research Design | 1 | 2011 | 23 | 0.090 |
Why?
|
| Marital Status | 1 | 2011 | 45 | 0.090 |
Why?
|
| Sodium, Dietary | 1 | 2011 | 9 | 0.090 |
Why?
|
| Social Class | 1 | 2012 | 145 | 0.090 |
Why?
|
| Hyponatremia | 1 | 2011 | 30 | 0.090 |
Why?
|
| Health Care Coalitions | 1 | 2011 | 9 | 0.090 |
Why?
|
| Oxygen Consumption | 1 | 2012 | 257 | 0.090 |
Why?
|
| Community-Institutional Relations | 1 | 2011 | 31 | 0.080 |
Why?
|
| Occupational Diseases | 1 | 2011 | 57 | 0.080 |
Why?
|
| Length of Stay | 1 | 2014 | 833 | 0.080 |
Why?
|
| Women's Health Services | 1 | 2009 | 14 | 0.080 |
Why?
|
| Sodium | 1 | 2011 | 340 | 0.080 |
Why?
|
| Linear Models | 2 | 2025 | 438 | 0.080 |
Why?
|
| Pediatrics | 1 | 2014 | 399 | 0.080 |
Why?
|
| Public Sector | 1 | 2009 | 13 | 0.080 |
Why?
|
| Spinal Fusion | 1 | 2014 | 348 | 0.080 |
Why?
|
| Molecular Epidemiology | 2 | 2020 | 58 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 378 | 0.070 |
Why?
|
| Registries | 1 | 2014 | 986 | 0.070 |
Why?
|
| HIV Serosorting | 2 | 2018 | 4 | 0.070 |
Why?
|
| Social Environment | 2 | 2020 | 195 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 7232 | 0.070 |
Why?
|
| Vaginal Discharge | 1 | 2007 | 2 | 0.070 |
Why?
|
| Diet | 1 | 2011 | 461 | 0.070 |
Why?
|
| Warts | 1 | 2007 | 12 | 0.070 |
Why?
|
| Ulcer | 1 | 2007 | 38 | 0.070 |
Why?
|
| Therapeutic Irrigation | 1 | 2007 | 66 | 0.070 |
Why?
|
| Hospitals, University | 1 | 2008 | 199 | 0.070 |
Why?
|
| Mucous Membrane | 1 | 2007 | 85 | 0.070 |
Why?
|
| Infant | 1 | 2014 | 3363 | 0.070 |
Why?
|
| Immunoglobulin A | 1 | 2007 | 91 | 0.070 |
Why?
|
| Vitamin D | 1 | 2008 | 273 | 0.060 |
Why?
|
| Diketopiperazines | 1 | 2025 | 6 | 0.060 |
Why?
|
| Multilevel Analysis | 1 | 2025 | 25 | 0.060 |
Why?
|
| Drug Trafficking | 1 | 2025 | 2 | 0.060 |
Why?
|
| Poisson Distribution | 1 | 2025 | 49 | 0.060 |
Why?
|
| Conflict of Interest | 1 | 2006 | 77 | 0.060 |
Why?
|
| Analysis of Variance | 1 | 2007 | 910 | 0.060 |
Why?
|
| Law Enforcement | 1 | 2025 | 12 | 0.060 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 777 | 0.060 |
Why?
|
| Hospitalization | 3 | 2022 | 943 | 0.060 |
Why?
|
| Asthma | 1 | 2014 | 1051 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 481 | 0.060 |
Why?
|
| Research Design | 2 | 2020 | 631 | 0.060 |
Why?
|
| Injections | 1 | 2025 | 126 | 0.060 |
Why?
|
| Interprofessional Relations | 1 | 2006 | 128 | 0.060 |
Why?
|
| Case Managers | 1 | 2024 | 3 | 0.060 |
Why?
|
| Alcoholic Beverages | 1 | 2024 | 14 | 0.060 |
Why?
|
| Pain | 1 | 2007 | 426 | 0.060 |
Why?
|
| Factor Analysis, Statistical | 1 | 2004 | 118 | 0.050 |
Why?
|
| Spatial Analysis | 1 | 2024 | 10 | 0.050 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 2004 | 6 | 0.050 |
Why?
|
| Iowa | 1 | 2004 | 35 | 0.050 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2004 | 28 | 0.050 |
Why?
|
| Hospitals, Community | 1 | 2004 | 35 | 0.050 |
Why?
|
| Pheochromocytoma | 1 | 2004 | 52 | 0.050 |
Why?
|
| Patient Admission | 1 | 2004 | 122 | 0.050 |
Why?
|
| Midwestern United States | 1 | 2023 | 91 | 0.050 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2004 | 85 | 0.050 |
Why?
|
| Genes, Viral | 1 | 2023 | 109 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2007 | 1958 | 0.050 |
Why?
|
| Parental Consent | 1 | 2023 | 36 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 3651 | 0.050 |
Why?
|
| Employment | 1 | 2022 | 57 | 0.050 |
Why?
|
| Policy | 1 | 2022 | 42 | 0.050 |
Why?
|
| Cause of Death | 1 | 2022 | 278 | 0.040 |
Why?
|
| Lost to Follow-Up | 1 | 2021 | 15 | 0.040 |
Why?
|
| Needle Sharing | 1 | 2020 | 15 | 0.040 |
Why?
|
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2020 | 1 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 204 | 0.040 |
Why?
|
| Informed Consent | 1 | 2023 | 281 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2013 | 599 | 0.040 |
Why?
|
| Health Personnel | 1 | 2022 | 241 | 0.040 |
Why?
|
| Parents | 1 | 2023 | 307 | 0.040 |
Why?
|
| Florida | 1 | 2019 | 63 | 0.040 |
Why?
|
| Mississippi | 1 | 2019 | 4 | 0.040 |
Why?
|
| New Orleans | 1 | 2019 | 7 | 0.040 |
Why?
|
| Anxiety | 1 | 2022 | 339 | 0.040 |
Why?
|
| Homophobia | 1 | 2019 | 4 | 0.040 |
Why?
|
| Africa | 1 | 2019 | 107 | 0.040 |
Why?
|
| Emotions | 1 | 2023 | 377 | 0.040 |
Why?
|
| Epidemiological Monitoring | 1 | 2019 | 43 | 0.040 |
Why?
|
| Knowledge | 1 | 2019 | 29 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 688 | 0.040 |
Why?
|
| Europe, Eastern | 1 | 2018 | 3 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 349 | 0.040 |
Why?
|
| Mouth | 1 | 2018 | 49 | 0.040 |
Why?
|
| New York | 1 | 2018 | 75 | 0.040 |
Why?
|
| Penis | 1 | 2018 | 65 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2018 | 71 | 0.030 |
Why?
|
| Asia | 1 | 2018 | 105 | 0.030 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 398 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2018 | 157 | 0.030 |
Why?
|
| Economic Competition | 1 | 2017 | 12 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2017 | 30 | 0.030 |
Why?
|
| Mobile Applications | 1 | 2018 | 79 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 668 | 0.030 |
Why?
|
| Exercise | 1 | 2020 | 354 | 0.030 |
Why?
|
| London | 1 | 2016 | 17 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2016 | 79 | 0.030 |
Why?
|
| Directive Counseling | 1 | 2015 | 35 | 0.030 |
Why?
|
| Preventive Health Services | 1 | 2015 | 39 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 255 | 0.030 |
Why?
|
| Family | 1 | 2016 | 332 | 0.030 |
Why?
|
| Algorithms | 1 | 2023 | 2014 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 539 | 0.030 |
Why?
|
| Ipratropium | 1 | 2014 | 18 | 0.030 |
Why?
|
| Spirometry | 1 | 2014 | 78 | 0.030 |
Why?
|
| Forced Expiratory Volume | 1 | 2014 | 136 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 258 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2017 | 644 | 0.020 |
Why?
|
| Safety Management | 1 | 2012 | 58 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2012 | 156 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 813 | 0.020 |
Why?
|
| Pressure | 1 | 2012 | 175 | 0.020 |
Why?
|
| Animals | 1 | 2011 | 28945 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2014 | 369 | 0.020 |
Why?
|
| Middle East | 1 | 2011 | 19 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2012 | 77 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 295 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2011 | 28 | 0.020 |
Why?
|
| Models, Organizational | 1 | 2011 | 48 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2014 | 1791 | 0.020 |
Why?
|
| Seasons | 1 | 2011 | 246 | 0.020 |
Why?
|
| Preoperative Care | 1 | 2012 | 418 | 0.020 |
Why?
|
| Disease Progression | 1 | 2014 | 1568 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2012 | 424 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2009 | 157 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 1933 | 0.020 |
Why?
|
| Mobile Health Units | 1 | 2007 | 12 | 0.020 |
Why?
|
| Tracheotomy | 1 | 2007 | 18 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 682 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2008 | 983 | 0.010 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2004 | 111 | 0.010 |
Why?
|
| Inflammation | 1 | 2008 | 1068 | 0.010 |
Why?
|
| Acute Disease | 1 | 2004 | 872 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2004 | 343 | 0.010 |
Why?
|
| Pregnancy | 1 | 2004 | 3240 | 0.010 |
Why?
|